July 2nd 2025
The company is voluntarily recalling one lot of cefazolin for injection, USP, 1 gram per vial due to customer complaints of the wrong product being included in a carton.
Charles River Partners with Bit Bio for Human Cell Suite Expansion
December 12th 2019Through the collaboration, Charles River plans to expand its suite of authentic human cells by utilizing Bit Bio’s target discovery, validation, and screening services to further the development of therapies with a higher chance of success in patients.
Astellas to Acquire Audentes for $3 Billion
December 3rd 2019The acquisition aids in the expansion of the Astellas Focus Area approach, which involves the creation of medicines for diseases with high unmet medical needs by identifying combinations of biology, therapeutic modality and technology based on emerging science.
Zelluna Immunotherapy and Glycostem Therapeutics Partner on Cell Therapies
November 25th 2019Biopharma company, Zelluna Immunotherapy, and clinical stage biotech, Glycostem Therapeutics, have entered into a partnership focused on the development and manufacture of allogeneic T-cell receptor guided Natural Killer cell therapies for the treatment of cancer.
Prisym ID’s Clinical Trial Solution Chosen for Medicines Manufacturing Innovation Centre Project
November 25th 2019Label management specialist, Prisym ID, announced that its clinical trial solution, PRISYM 360, has been chosen by CME to be part of a just in time clinical trials handling system for the Medicines Manufacturing Innovation Centre project.
Sangamo Gains MHRA Authorization for Clinical Trial of CAR-Treg Therapy
November 21st 2019Sangamo Therapeutics has revealed that the United Kingdom’s Medicines Healthcare Products Regulatory Agency (MHRA) has authorized the first in-human clinical trial evaluating a chimeric antigen receptor regulatory T cell (CAR-Treg) therapy.